Diasome Pharmaceuticals said today that it inked a funding deal that could bring the company up to $30 million. The round was led by Medicxi and contributed to by JDRF T1D Fund, Black Beret Life Sciences and McDonald Partners.
The Cleveland-based company said it plans to use the funds to support the clinical development of its hepatocyte directed vesicles (HDV) technology. Diasome’s additive is designed to direct the delivery of commercial insulin therapies to the liver’s hepatocytes.
Get the full story at our sister site, Drug Delivery Business News.
The post Diasome lands $30m to fund clinical trials of liver-targeted insulin appeared first on MassDevice.
from MassDevice http://ift.tt/2sGn2Dk
Cap comentari:
Publica un comentari a l'entrada